Latest Articles

Chronic Myeloid Leukemia Research Indicates Imatinib Is Effective in Pediatric Patients With Chronic Phase CML

Research Indicates Imatinib Is Effective in Pediatric Patients With Chronic Phase CML

A large, long-term study found a 97% event-free survival rate at 18 months.

Lung Cancer Research Advances for Mutant KRAS-Driven Lung Adenocarcinoma

Research Advances for Mutant KRAS-Driven Lung Adenocarcinoma

Two recent studies have found that signaling from other ERBB family members is necessary for survival and proliferation in KRAS-driven tumors, and that afatinib and neratinib produce an antitumor response.

Multiple Myeloma Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy

Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy

Selecting therapies for patients with multiple myeloma is challenging because the disease is inherently heterogeneous.

General Oncology Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

Skin Cancer Next-Generation Sequencing Adds Value by Detecting More Mutations Than Polymerase Chain Reaction in Melanoma

Next-Generation Sequencing Adds Value by Detecting More Mutations Than Polymerase Chain Reaction in Melanoma

Since next-generation sequencing reflex testing has been implemented at Case Western Reserve University School of Medicine, several cases of potentially actionable mutations have been identified that would not have been caught by PCR alone.

Multiple Myeloma Bone Imaging With Improved Modalities in Multiple Myeloma

Bone Imaging With Improved Modalities in Multiple Myeloma

Bone imaging is a critical aspect of care for patients with multiple myeloma, and recent advances in imaging modalities have improved detection of lytic lesions and bone marrow involvement—but incorporating these new modalities into clinical practice has been challenging.

General Oncology Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

General Oncology Sildenafil and Cancer: The Potential Positives

Sildenafil and Cancer: The Potential Positives

Examining the costs and benefits of repurposing sildenafil as a cancer medication.

Multiple Myeloma Value, Not Cost, Should Be Considered for Myeloma Treatment

Value, Not Cost, Should Be Considered for Myeloma Treatment

Even though cancer drugs only account for approximately 1% of the total health care spend, physicians can serve as advocates for patients struggling to afford recommended treatments.

General Oncology Q&A With Frank Luh, MD, MS, MHA and Yun Yen, MD, PhD, FACP: Looking to Broaden CMS Coverage for NGS Tests

Q&A With Frank Luh, MD, MS, MHA and Yun Yen, MD, PhD, FACP: Looking to Broaden CMS Coverage for NGS Tests

Restricting use to FDA-approved NGS tests is not an absolute rule that must last forever. But it's a good start, say two physicians.

Prostate Cancer New Therapeutic Directions in the Management of Prostate Cancer

New Therapeutic Directions in the Management of Prostate Cancer

According to experts, PARP inhibition, radiopharmaceuticals, and immunotherapy could revolutionize how prostate cancer is treated in the coming decade.

Gastrointestinal Cancers Colon Cancer Screening: American Cancer Society Guidelines Update

Colon Cancer Screening: American Cancer Society Guidelines Update

An increase in the appearance of colorectal cancer incidence in younger people has prompted the American Cancer Society to revise its current screening guidelines.

Bladder Cancer Adding Gemcitabine at the Time of Resection Reduces Recurrence, Cost in Early-Stage Bladder Cancer

Adding Gemcitabine at the Time of Resection Reduces Recurrence, Cost in Early-Stage Bladder Cancer

Though early-stage bladder cancer is infrequently fatal, the decrease in recurrence rates has a meaningful impact on the quality of life for patients as well as treatment costs.

Skin Cancer Novel Targets, Treatments Needed for Melanomas Not Responding to Targeted Immunotherapies

Novel Targets, Treatments Needed for Melanomas Not Responding to Targeted Immunotherapies

Novel targets in the treatment of melanoma was a hot topic of discussion during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

Renal Cell Carcinoma Heading Toward Personalized Management of Advanced Kidney Cancer

Heading Toward Personalized Management of Advanced Kidney Cancer

The heterogeneity of kidney cancer makes each of the tumors unique and treatment decisions based on tumor characteristics especially challenging.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs